Clinical Trial Update: The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines. [Phase 2]

View source ↗

Summary

Phase 2 trial in recruitment evaluating the combination of chidamide and regorafenib with iparomlimab and tuvonralimab for advanced colorectal cancer in third-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Chidamide (chidamide)
• Stivarga (regorafenib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer | Phase 2 | Status: RECRUITING